Quarterly assessment of short-acting β2-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the united states

Journal of Asthma

Volumn 47, Issue 6, 2010, Pages 660-666

  Silver, Harris S ^a   Blanchette, Christopher M ^b   Kamble, Shital ^c   Petersen, Hans ^a   Letter, Matthew ^a   Meddis, David ^d   Gutierrez, Benjamin ^d  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Asthma control; Asthma exacerbation; Health services research; Outcomes research; Pharmacoepidemiology; SABA utilization

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG USE; EMERGENCY WARD; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METERED DOSE INHALER; NEBULIZATION; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 77955532317     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770901003702824     Document Type: Article

References (28)

1. Mannino D, Homa D, Akinbami L, Moorman J, Gwynn C, Redd S. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ 2002; 51:1-13.
2. Rodrigo G, Rodrigo C, Hall J. Acute asthma in adults: a review. Chest 2004; 125:1081-1102.
3. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma 2009; 46:73-80.
4. Malone D, Lawson K, Smith D. Asthma: an analysis of high-cost patients. Pharm Pract Manag Q 2000; 20:12-20.
5. National Asthma Education and Prevention Program (NAEPP) Expert Panel. National Asthma Education and Prevention Program (NAEPP) expert panel report 3: guidelines for the diagnosis andmanagement of asthma. J Allergy Clin Immunol 2007; 120:S94-S138.
6. Donahue J, Weiss S, Livingston J, Goestch M, Greineder D, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887-891. (Pubitemid 27123948)
7. Senthilselvan A, Lawson J, Rennie D, Dosman J. Regular use of corticosteroids and low use of short-acting ?2 -agonists can reduce asthma hospitalization. Chest 2005; 127:1242-1251.
8. Smith M, Rascati K, Barner J. A descriptive analysis of asthma-related medical services and prescription utilization among recipients in aMedicaid program. J Asthma 2005; 42:447-453.
9. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma, and Immunology and Joint Council of Allergy,Asthma and Immunology.Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005; 116:S3-S11.
10. Stoloff S, Boushey H. Severity, control, and responsiveness in asthma. J Allergy Clin Immunol 2006; 117:544-548.
11. Juniper E, OByrne P, Guyatt G, Ferrie P, King D. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-907. (Pubitemid 29519356)
12. Nathan R, Sorkness C, Kosinski M, Schatz M, Li J, Marcus P. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
13. Vollmer W, Markson L, OConnor E, Sanocki L, Fitterman L. Association of asthma control with health care utilization and quality of life. Am J Resp Crit Care Med 1999; 160:1647-1652.
14. Watson L, Kerstjens H, Rabe K, Kiri V, Visick G, Postma D. Obtaining optimal control in mild asthma: theory and practice. Fam Pract 2005; 22:305-310.
15. Schatz M, Nakahiro R, Crawford W, Mendoza G, Mosen D, Stibolt T. Asthma quality-of-care markers using administrative data. Chest 2005; 128:1968-1973.
16. Schatz M, Zeiger R, Vollmer W, Mosen D, Apter A. Development and validation of a medication intensity scale derived from computerized pharmacy data that predicts emergency hospital utilization for persistent asthma. Am J Manag Care 2006; 12:478-484.
17. Schatz M, Zeiger R, Vollmer W, Mosen D, Cook E. Determinants of future long-term asthma control. J Allergy Clin Immunol 2006; 118: 1048-1053.
18. Stempel D, McLaughin T, Stanford R, Fuhlbrigge A. Patterns of asthma control: a 3-year analysis of patient claims. J Allergy Clin Immunol 2005; 115:935-939.
19. Paris J, Peterson E, Wells K, Pladewell M, Burchard E, Choudhry S, et al. Relationship between recent short-acting ?-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol 2008; 101:482-487.
20. Schatz M, Zeiger R, Vollmer W, Mosen D, Apter A. Validation of a betaagonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117:995-1000.
21. Glauber J, Fuhlbrigge A. Stratifying asthma populations by medication use: how you count counts. Ann Allergy Asthma Immunol 2002; 88:451-456.
22. Chan J, Hui R, Spence M. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm 2007; 13:21-27.
23. Diette G,Wu A, Skinner E, Markson L, Clark R. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled betaagonists and underuse of inhaled corticosteroids. Arch Intern Med 1999; 159:2697-2704.
24. Lynd L, Guh D, Pare P, Anis A. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada. Chest 2002; 122:1973-1981.
25. OConnor R, ODonnell J, Pinto L, Wiener D, Legorreta A. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002; 121:1028-1035.
26. Stempel D,Mauskopf J, McLaughin T, Yazdani C, Stanford R. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227-234.
27. Ten Brinke A, Sterk P, Masclee A, Spinhoven P, Schmidt J. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812-818.
28. Markovitz B, Andresen E. Lack of insurance coverage and urgent care use for asthma: a retrospective cohort study. BMC Public Health 2006; 6:14.